Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 6/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 6/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 6/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | RRM1 | P23921 | 3/20 | 0.35 |
| ▸ | RRM2B | Q7LG56 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12565316 | 0.86 | LMNA (0.42) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL3267365 | 0.85 | LMNA (0.42) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL3272238 | 0.81 | LMNA (0.46) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL31690278 | 0.79 | LMNA (0.39) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL31472123 | 0.77 | ABCC9 (0.35) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL19682929 | 0.76 | CHRM2 (0.42) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL1266120 | 0.75 | LMNA (0.35) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL25166116 | 0.72 | MAOB (0.40) | LMNAMAPTABCC9ABCC8KCNJ11 | |
| SCHEMBL19682918 | 0.72 | LMNA (0.42) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL19682599 | 0.72 | LMNA (0.36) | LMNAMAPTABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3841086-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020041301-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | LMNA 1541/4885MAPT 3038/4885ABCC9 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.